Study SC-101 in Subjects With Advanced Malignancies
ConditionAdvanced Solid Tumor
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorTianjin ConjuStar Biologics Co., Ltd.
About this trial
This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.
Eligibility criteria
Qualifiers
Subjects voluntarily agree to participate in the study and sign the Informed Consent Form (ICF).
18 to 80 years of age at the time of signature of the ICF, without gender limitation.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Life expectancy of ≥ 3 months as assessed by the investigator.
Disqualifiers
History of other malignancy(ies) within 3 years before signing the ICF, except for non-melanoma skin cancer, cervical carcinoma in situ, or other malignant tumors that are considered to have been cured.
Any anticancer therapy, including any investigational drug, within 2 weeks before the first dose of the study drug.
Uncontrolled central nervous system metastases.
Prior treatment with Nectin-4-targeting anti-cancer therapy.
Trial design
Treatments tested in this trial
- SC-101
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov